ACRO Announces 2023 Officers and New Member
WASHINGTON, DC – Washington DC – ACRO is pleased to announce that its Board of Directors has elected Paul Kirchgraber, M.D., Executive…
WASHINGTON, DC – Washington DC – ACRO is pleased to announce that its Board of Directors has elected Paul Kirchgraber, M.D., Executive…
WASHINGTON, DC – Today, the Association of Clinical Research Organizations (ACRO)’s DCT Working Party releases the latest addition to its DCT Toolkit:…
Our member companies have faced widespread clinical trial disruptions in the past few years – from the global pandemic, to the war…
WASHINGTON, DC – This week, the Association of Clinical Research Organizations (ACRO)’s Diversity and Inclusion in Clinical Trials committee is proud to…
The below is an Op-Ed authored by ACRO Chair, Jackie Kent, for MedPage Today on August 6, 2022. Read the full article…
With bipartisan sponsorship from Representatives Pallone (D-NJ) and McMorris Rodgers (R-WA) the American Data Privacy and Protection Act (ADPPA), which would create…
ACRO Celebrates 20 Years! 20 years ago, contract research organizations were still relatively new players within the clinical research enterprise, and the…
Washington, DC — On March 16, 2022, ACRO’s Board of Directors was joined by more than 125 clinical research stakeholders – including…
Washington DC – The Association of Clinical Research Organizations (ACRO) is pleased to announce that its Board of Directors has elected Jackie…
The below is the Op-Ed authored by ACRO Executive Director, Doug Peddicord for Morning Consult on November 3, 2021. Read the full…
Today, ACRO released its DCT Toolkit, which lays out a vision for how decentralized clinical trials can be planned and executed now…
Washington, DC — The Association of Clinical Research Organizations (ACRO) congratulates Representatives Diana DeGette (D-CO) and Fred Upton (R-MI) on the release…
Risk-based monitoring (RBM) is a powerful tool for efficiently ensuring patient safety and data integrity in a clinical trial, enhancing overall trial…
Washington DC – The Association of Clinical Research Organizations (ACRO) is pleased to announce that its Board of Directors has elected Steve…
Ironically, the Pfizer-BioNTech Covid-19 vaccine program did not take “Operation Warp Speed” funding. Even more ironic is the fact that Pfizer got…
It was a familiar scenario: A rare disease area of oncology. A new drug candidate. A desire to assess efficacy as safely and quickly as possible, so that if successful, a new therapy could get approved and change lives. But this desire could have been tempered by reality: the trial was going to be challenging and slow…
For the clinical research industry, technological tools improve trial continuity, and generate data that helps power more robust monitoring of safety and quality. They can also be a natural fit for patients. IQVIA also sees study participants liking the direct shipment of medicines, telehealth interactions and at-home visits. In the COVID era and beyond, designing more trials with these kinds of technology-enabled strategies is going to help more people by lowering barriers to participation, and speeding the development of new medicines.
Diverse technology solutions, like patient telehealth visits, accessing electronic medical records (EMRs) or remote source data verification, can generate vast amounts of data. As the clinical research industry evolves towards its next “new normal” with a higher baseline level of remote monitoring, IQVIA is considering the implications of increasing data access. Are we ready?
We all had a flurry of unprecedented activity. We were assessing risks to patients and data, and putting in place mitigation strategies to preserve continuity of the studies.” Those strategies involved thousands of amendments to protocols, adapting to sudden changes that impacted patients and sites around the world.
A key pillar in the COVID-19 battle is the rapid development of a safe and effective vaccine. As vaccine R&D shifted into gear and then accelerated throughout 2020, with a rapidly growing number of candidates, platforms and manufacturers, it appeared that a bottleneck in this race could actually be the ability to enroll participants.